SEC Filings
Akebia Swings To $14.4 Million Loss Despite Vafseo's Growing Patient Count
Auryxia sales fell under pressure from generic competition, while inventory reductions limited Vafseo revenue.
AKBA
Akebia Therapeutics (AKBA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Akebia Has Until April 19, 2027 To Lift Its Stock Back Above $1.00 Or Face Delisting Risk
Nasdaq flagged the kidney-drug maker's shares after 30 straight business days below the minimum bid; a reverse stock split is on the table.
SEC Filings
Akebia's Chief Commercial Officer Resigns Effective November 6, Then Moves To A Paid Consulting Role
Nicholas Grund will advise Akebia through April 30, 2027 at an hourly rate, according to an 8-K filed Wednesday.